Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endosonography | 12 | 2016 | 55 | 1.570 |
Why?
|
| Endoscopes, Gastrointestinal | 12 | 2010 | 12 | 0.780 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 6 | 2016 | 30 | 0.620 |
Why?
|
| Endoscopy, Gastrointestinal | 9 | 2013 | 24 | 0.550 |
Why?
|
| Gallbladder Diseases | 2 | 2010 | 9 | 0.540 |
Why?
|
| Cholestasis | 3 | 2012 | 18 | 0.440 |
Why?
|
| Barrett Esophagus | 1 | 2014 | 3 | 0.420 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 26 | 0.420 |
Why?
|
| Biliary Tract Diseases | 3 | 2012 | 12 | 0.410 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 44 | 0.410 |
Why?
|
| Biliary Tract | 2 | 2012 | 7 | 0.390 |
Why?
|
| Catheter Ablation | 1 | 2014 | 116 | 0.390 |
Why?
|
| Lymphangioma, Cystic | 1 | 2012 | 1 | 0.370 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 321 | 0.350 |
Why?
|
| Pancreatic Diseases | 3 | 2009 | 21 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 135 | 0.330 |
Why?
|
| Polyps | 1 | 2010 | 9 | 0.320 |
Why?
|
| Cholecystectomy | 1 | 2010 | 21 | 0.320 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 103 | 0.300 |
Why?
|
| Liver Diseases | 1 | 2009 | 76 | 0.290 |
Why?
|
| Humans | 42 | 2019 | 34562 | 0.270 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2013 | 65 | 0.250 |
Why?
|
| Liver | 1 | 2009 | 513 | 0.240 |
Why?
|
| Intestinal Mucosa | 3 | 2019 | 75 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 5 | 2009 | 54 | 0.230 |
Why?
|
| Liver Failure | 1 | 2005 | 22 | 0.220 |
Why?
|
| Stents | 2 | 2009 | 167 | 0.220 |
Why?
|
| Colonoscopy | 4 | 2019 | 46 | 0.200 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 12 | 0.190 |
Why?
|
| Mucins | 1 | 2003 | 18 | 0.190 |
Why?
|
| Equipment Design | 11 | 2010 | 192 | 0.190 |
Why?
|
| Epithelial Cells | 1 | 2003 | 148 | 0.180 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 614 | 0.180 |
Why?
|
| Catheterization | 3 | 2010 | 62 | 0.170 |
Why?
|
| Device Approval | 2 | 2010 | 6 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2010 | 53 | 0.160 |
Why?
|
| Endoscopy, Digestive System | 2 | 2009 | 11 | 0.150 |
Why?
|
| Male | 11 | 2019 | 20739 | 0.140 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 542 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2008 | 34 | 0.130 |
Why?
|
| Technology Assessment, Biomedical | 4 | 2009 | 11 | 0.120 |
Why?
|
| Digestive System Diseases | 1 | 2016 | 6 | 0.120 |
Why?
|
| Choledocholithiasis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2016 | 55 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2016 | 22 | 0.120 |
Why?
|
| Female | 10 | 2016 | 21531 | 0.110 |
Why?
|
| Endoscopy | 2 | 2019 | 56 | 0.110 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2013 | 12 | 0.100 |
Why?
|
| Middle Aged | 7 | 2019 | 12726 | 0.100 |
Why?
|
| Sphincterotomy, Endoscopic | 2 | 2010 | 4 | 0.100 |
Why?
|
| Lymphatic Diseases | 1 | 2012 | 11 | 0.100 |
Why?
|
| Surgical Instruments | 2 | 2009 | 25 | 0.090 |
Why?
|
| Equipment Safety | 5 | 2010 | 21 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2012 | 120 | 0.090 |
Why?
|
| Video Recording | 2 | 2010 | 64 | 0.090 |
Why?
|
| Adult | 5 | 2016 | 10030 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 230 | 0.080 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2010 | 4 | 0.080 |
Why?
|
| Pancreatitis, Chronic | 1 | 2010 | 8 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2010 | 29 | 0.080 |
Why?
|
| Gastrostomy | 1 | 2010 | 17 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2008 | 823 | 0.080 |
Why?
|
| Calculi | 1 | 2009 | 2 | 0.080 |
Why?
|
| Gallstones | 1 | 2009 | 11 | 0.080 |
Why?
|
| Microscopy | 1 | 2009 | 28 | 0.080 |
Why?
|
| Cathartics | 1 | 2009 | 5 | 0.080 |
Why?
|
| Hemostasis, Surgical | 1 | 2009 | 12 | 0.080 |
Why?
|
| Disinfection | 1 | 2009 | 6 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 80 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2009 | 22 | 0.070 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2009 | 13 | 0.070 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 33 | 0.070 |
Why?
|
| Gallbladder Neoplasms | 1 | 2009 | 35 | 0.070 |
Why?
|
| Capsule Endoscopy | 1 | 2008 | 4 | 0.070 |
Why?
|
| Gastric Mucosa | 1 | 2008 | 14 | 0.070 |
Why?
|
| Endoscopes | 1 | 2008 | 4 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2009 | 129 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 38 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 397 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2008 | 74 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 922 | 0.070 |
Why?
|
| Forecasting | 1 | 2008 | 153 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 170 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2007 | 45 | 0.070 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2007 | 7 | 0.070 |
Why?
|
| Coloring Agents | 1 | 2007 | 32 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 57 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3623 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 24 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2016 | 3825 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 600 | 0.060 |
Why?
|
| Prognosis | 1 | 2010 | 1606 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 2367 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 939 | 0.060 |
Why?
|
| Controlled Clinical Trials as Topic | 3 | 2010 | 11 | 0.060 |
Why?
|
| Body Composition | 1 | 2007 | 415 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 232 | 0.050 |
Why?
|
| Health Status | 1 | 2006 | 411 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 354 | 0.050 |
Why?
|
| Uridine Triphosphate | 1 | 2003 | 1 | 0.050 |
Why?
|
| Goblet Cells | 1 | 2003 | 5 | 0.050 |
Why?
|
| United States | 5 | 2010 | 4278 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2003 | 11 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2003 | 8 | 0.050 |
Why?
|
| Second Messenger Systems | 1 | 2003 | 8 | 0.050 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2003 | 11 | 0.050 |
Why?
|
| Species Specificity | 1 | 2003 | 101 | 0.050 |
Why?
|
| Bronchi | 1 | 2003 | 41 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2003 | 75 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 123 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 69 | 0.050 |
Why?
|
| Adenosine | 1 | 2003 | 74 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 203 | 0.050 |
Why?
|
| Trachea | 1 | 2003 | 56 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2008 | 1508 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2003 | 124 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2003 | 296 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2016 | 597 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 889 | 0.040 |
Why?
|
| Diet, Gluten-Free | 1 | 2019 | 3 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 12 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 20 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2019 | 88 | 0.040 |
Why?
|
| Diarrhea | 1 | 2019 | 59 | 0.040 |
Why?
|
| Obesity | 1 | 2007 | 1246 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 123 | 0.040 |
Why?
|
| Collagen | 1 | 2019 | 240 | 0.040 |
Why?
|
| Needles | 2 | 2009 | 33 | 0.040 |
Why?
|
| Child | 2 | 2016 | 2614 | 0.030 |
Why?
|
| Enema | 2 | 2009 | 6 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 417 | 0.030 |
Why?
|
| Mice | 1 | 2003 | 2720 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4157 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 500 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 2463 | 0.030 |
Why?
|
| Cholangiography | 1 | 2016 | 12 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 544 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2008 | 565 | 0.030 |
Why?
|
| Animals | 2 | 2010 | 8578 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 988 | 0.030 |
Why?
|
| Abdomen | 1 | 2012 | 52 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1355 | 0.020 |
Why?
|
| Aged | 2 | 2016 | 11022 | 0.020 |
Why?
|
| Compassionate Use Trials | 1 | 2010 | 3 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2010 | 7 | 0.020 |
Why?
|
| Medical Device Recalls | 1 | 2010 | 2 | 0.020 |
Why?
|
| Current Procedural Terminology | 1 | 2010 | 3 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2010 | 15 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 110 | 0.020 |
Why?
|
| Lasers, Gas | 1 | 2009 | 3 | 0.020 |
Why?
|
| Pancreas | 1 | 2010 | 108 | 0.020 |
Why?
|
| Hemostatics | 1 | 2009 | 13 | 0.020 |
Why?
|
| Syringes | 1 | 2009 | 5 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 2009 | 12 | 0.020 |
Why?
|
| Laser Coagulation | 1 | 2009 | 13 | 0.020 |
Why?
|
| Ligation | 1 | 2009 | 65 | 0.020 |
Why?
|
| Device Removal | 1 | 2009 | 44 | 0.020 |
Why?
|
| Dissection | 1 | 2008 | 18 | 0.020 |
Why?
|
| Miniaturization | 1 | 2008 | 5 | 0.020 |
Why?
|
| Fiber Optic Technology | 1 | 2008 | 15 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 43 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2008 | 19 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 2008 | 8 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 3805 | 0.020 |
Why?
|
| Safety Management | 1 | 2008 | 33 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2008 | 56 | 0.020 |
Why?
|
| Safety | 1 | 2007 | 82 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 100 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2008 | 168 | 0.020 |
Why?
|
| Injections | 1 | 2007 | 76 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 113 | 0.020 |
Why?
|
| Rest | 1 | 2007 | 53 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2006 | 3 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2006 | 7 | 0.020 |
Why?
|
| Occult Blood | 1 | 2006 | 12 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 176 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 245 | 0.020 |
Why?
|
| Energy Intake | 1 | 2007 | 138 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2006 | 72 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 306 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 305 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 149 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2006 | 133 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2007 | 169 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 343 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 596 | 0.010 |
Why?
|
| Motor Activity | 1 | 2007 | 356 | 0.010 |
Why?
|
| Mass Screening | 1 | 2006 | 269 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 439 | 0.010 |
Why?
|
| Neoplasms | 1 | 2007 | 793 | 0.010 |
Why?
|